Please login to the form below
Kyorin
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Kyorin's Japan sales performance.
New data shows Roche's Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses
The treatment is approved in 58 countries, including the United States, Canada, Japan, South Korea and the European Union.
Sandoz completes acquisition of GSK’s cephalosporin business
GSK will also retain full brand rights in China (excluding Taiwan, Hong Kong and Macau), India, Pakistan and Egypt and to certain brands in Japan.
CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
as we do in the US and Japan,” he added.
AstraZeneca clears latest hurdle for Alexion acquisition after EU clearance
The EU clearance comes after similar competition clearances in the US, Japan and other global regulatory agencies, AZ said in a statement.
AZ, HUTCHMED win first approval for MET inhibitor Orpathys in China
Japan’s medicines regulator.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Competitive salary offered
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- US demand for COVID-19 antibody treatments rising fast
- Assessing the value of interim analyses in clinical trials
- AstraZeneca chooses Ireland for $360m manufacturing site
- FDA accepts Regeneron’s REGEN-COV for priority review for treatment of COVID-19
- New data shows Roche's Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses
- Beyond yoga and smoothies – providing real support for employee well-being
- Driving Healthcare Decisions with Natural Language Processing
- FDA approves Eli Lilly’s Verzenio in high risk early breast cancer
- Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- Novo Nordisk settles US insulin pricing dispute for $100m
- US demand for COVID-19 antibody treatments rising fast
- Sandoz completes acquisition of GSK’s cephalosporin business
- Public is more comfortable with health data sharing if they know it is to support breakthrough treatments and vaccines
- Robust Review: Surrogate Endpoints
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
- Digital technologies: Pharma’s answer to achieving net zero emissions?
- ...
